Working to Eradicate Gynecologic Cancers

Mariusz Bidzinski, MD, PhD

Department of Gynecologic Oncology
Holycross Cancer Center
Artwinskiego Street 3
Kielce Poland 25-734

Papers:
448 - Poster Session B CA-125 as a response marker for vintafolide+pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer: the PRECEDENT trial 449 - Poster Session B Adverse event profile by folate receptor status for vintafolide+pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer